Clinic
Aurora Health Care Central, INC.
Aurora Health Care Central, INC. was paid $12.39M by Medicaid between Jan 2018 and Dec 2024, across 239 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 13% of everything it billed.
33Billing provider infoAURORA HEALTH CARE CENTRAL, INC.
SHEBOYGAN, WI 53081
SHEBOYGAN, WI 53081
33aNPI1922053107assigned 05/24/2006
33bProvider typeClinic/Center
28Total paid$12.39M
24GClaims593,862
24DCodes billed239
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Wisconsin
Rank by total paid#3 of 102
Median peer was paid$54K
This provider vs. median231×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,210 | $1.51M | |
| 2019 | 71,668 | $1.56M | |
| 2020 | 68,858 | $1.39M | |
| 2021 | 98,980 | $2.07M | |
| 2022 | 97,962 | $1.87M | |
| 2023 | 107,720 | $2.11M | |
| 2024incomplete | 80,464 | $1.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 12,394 | 9,287 | $1.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 22,642 | 19,687 | $1.38M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 17,651 | 15,171 | $966K |
| H2012 | Behavioral health day treatment, per hour | 6.2% | 19,454 | 1,237 | $766K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 11,475 | 9,829 | $664K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 13,594 | 5,024 | $421K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 5,018 | 4,475 | $382K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 5,170 | 4,547 | $367K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.9% | 4,140 | 3,201 | $361K |
| 80053 | Comprehensive metabolic panel | 2.9% | 26,156 | 19,477 | $360K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 4,885 | 4,383 | $308K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 4,288 | 2,744 | $265K |
227 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 1,474 | $263K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 4,608 | $243K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 5,470 | $203K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 32,835 | $199K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.4% | 8,420 | $168K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 1,998 | $167K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,744 | $138K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 2,937 | $135K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 3,611 | $130K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 1,313 | $127K |
| 84484 | <1% | 11,411 | $119K | |
| 83880 | <1% | 3,693 | $115K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,775 | $112K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,250 | $88K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,403 | $83K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,618 | $82K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 451 | $79K |
| 83735 | <1% | 14,772 | $77K | |
| 82077 | <1% | 3,485 | $73K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,625 | $71K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 956 | $70K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 588 | $64K |
| 84702 | <1% | 3,914 | $61K | |
| 84145 | <1% | 3,268 | $60K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,722 | $58K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,167 | $57K |
| 83690 | <1% | 9,786 | $56K | |
| 80305 | <1% | 4,619 | $55K | |
| 81025 | <1% | 5,919 | $55K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,828 | $52K |
| 97161 | <1% | 1,345 | $51K | |
| 82962 | <1% | 5,974 | $51K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,035 | $50K |
| 88720 | <1% | 712 | $40K | |
| G0378 | Hospital observation service, per hour | <1% | 2,565 | $40K |
| 80047 | <1% | 2,096 | $40K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,232 | $38K |
| 83605 | <1% | 4,090 | $37K | |
| 85730 | <1% | 7,474 | $36K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,833 | $35K |
| 85610 | <1% | 9,411 | $34K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,055 | $33K |
| 0240U | <1% | 1,256 | $33K | |
| 87040 | <1% | 2,885 | $33K | |
| 96415 | <1% | 471 | $29K | |
| 81001 | <1% | 8,003 | $29K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 357 | $24K |
| 97597 | <1% | 556 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 282 | $21K |
| 80143 | <1% | 1,773 | $21K | |
| 81003 | <1% | 4,723 | $21K | |
| 80179 | <1% | 1,757 | $20K | |
| 80076 | <1% | 2,504 | $19K | |
| 85379 | <1% | 2,204 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 453 | $17K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 98 | $16K |
| 97162 | <1% | 583 | $16K | |
| 76830 | Ultrasound, transvaginal | <1% | 581 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 454 | $16K |
| 93975 | <1% | 364 | $15K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 346 | $15K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 516 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,025 | $14K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 529 | $13K |
| 82075 | <1% | 1,242 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 83 | $13K |
| 70498 | <1% | 114 | $11K | |
| 85027 | <1% | 2,206 | $11K | |
| 87081 | <1% | 342 | $11K | |
| 96367 | <1% | 192 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,624 | $10K |
| 87077 | <1% | 649 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 46 | $10K |
| 70486 | <1% | 282 | $10K | |
| 82550 | <1% | 1,745 | $9K | |
| 93971 | <1% | 485 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 430 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 355 | $8K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 214 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 142 | $8K |
| 86850 | <1% | 441 | $8K | |
| 43248 | <1% | 41 | $8K | |
| 97165 | <1% | 201 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 424 | $7K |
| 87186 | <1% | 892 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 139 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 65 | $6K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $6K |
| 12001 | <1% | 59 | $6K | |
| 86900 | <1% | 847 | $6K | |
| 70496 | <1% | 57 | $6K | |
| 82803 | <1% | 297 | $6K | |
| 90715 | <1% | 234 | $5K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 16 | $5K |
| 86140 | <1% | 1,222 | $5K | |
| 97035 | <1% | 416 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,024 | $4K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,752 | $4K |
| 82728 | <1% | 384 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 309 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,026 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 73 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,356 | $3K |
| 97166 | <1% | 116 | $3K | |
| 62323 | <1% | 16 | $3K | |
| 87807 | <1% | 165 | $2K | |
| 94060 | <1% | 70 | $2K | |
| 95811 | <1% | 12 | $2K | |
| 84703 | <1% | 291 | $2K | |
| 73630 | <1% | 516 | $2K | |
| 87210 | <1% | 145 | $2K | |
| 86901 | <1% | 824 | $2K | |
| 93356 | <1% | 14 | $2K | |
| 94729 | <1% | 86 | $2K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,335 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 221 | $2K |
| 71250 | <1% | 54 | $1K | |
| 97116 | <1% | 129 | $1K | |
| 76536 | <1% | 41 | $1K | |
| 12011 | <1% | 13 | $1K | |
| 87088 | <1% | 193 | $1K | |
| 83615 | <1% | 211 | $892.93 | |
| 87070 | <1% | 15 | $842.01 | |
| 85652 | <1% | 424 | $774.27 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $753.43 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,100 | $647.81 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,065 | $580.60 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,142 | $541.16 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 415 | $430.48 |
| 83550 | <1% | 71 | $410.07 | |
| 90686 | <1% | 16 | $371.97 | |
| 90674 | <1% | 20 | $371.60 | |
| 82607 | <1% | 52 | $352.13 | |
| 73130 | <1% | 325 | $333.30 | |
| 80061 | Lipid panel | <1% | 42 | $325.14 |
| 82565 | <1% | 15 | $312.14 | |
| 83540 | <1% | 72 | $303.84 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,401 | $283.21 |
| 73610 | <1% | 569 | $273.65 | |
| 94726 | <1% | 56 | $273.57 | |
| 36592 | <1% | 19 | $230.21 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,613 | $193.64 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,709 | $165.91 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,891 | $160.63 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 81 | $158.07 |
| 88307 | <1% | 25 | $157.81 | |
| 82010 | <1% | 30 | $153.28 | |
| 87205 | <1% | 43 | $140.83 | |
| 96376 | <1% | 3,011 | $94.57 | |
| 82746 | <1% | 25 | $93.58 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,057 | $86.14 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,955 | $85.91 |
| 84439 | <1% | 12 | $84.63 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 872 | $82.80 |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,769 | $80.61 |
| 74018 | <1% | 160 | $69.20 | |
| 73030 | <1% | 251 | $59.45 | |
| 73562 | <1% | 513 | $52.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,679 | $49.85 |
| J2704 | Injection, propofol, 10 mg | <1% | 9,206 | $49.26 |
| 82271 | <1% | 15 | $43.03 | |
| 80320 | <1% | 348 | $40.31 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,660 | $25.76 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,090 | $23.50 |
| 85014 | <1% | 13 | $20.10 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 599 | $18.51 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,308 | $17.37 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,028 | $9.34 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,848 | $6.23 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,634 | $5.35 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,463 | $2.94 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,958 | $2.58 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 886 | $1.20 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 13 | $0.04 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 658 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,718 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,000 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 118 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,245 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 220 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 295 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 213 | $0.00 |
| A4212 | Non-coring needle or stylet with or without catheter | 0% | 254 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 72 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 150 | $0.00 |
| 73110 | 0% | 45 | $0.00 | |
| A4565 | Slings | 0% | 26 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 30 | $0.00 |
| 73080 | 0% | 44 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 29 | $0.00 |
| 73590 | 0% | 29 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 31 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 84 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 21 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 57 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| 72100 | 0% | 13 | $0.00 | |
| C1769 | Guide wire | 0% | 1,283 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 228 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,016 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 421 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 59 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 947 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 191 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 220 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 776 | $0.00 |
| 88304 | 0% | 113 | $0.00 | |
| 76801 | 0% | 16 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 51 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 127 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 73 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 28 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 43 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 38 | $0.00 |
| 71101 | 0% | 12 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| 88300 | 0% | 13 | $0.00 | |
| 36416 | 0% | 48 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 79 | $0.00 |
| 36000 | 0% | 25 | $0.00 | |
| 73502 | 0% | 40 | $0.00 | |
| 74022 | 0% | 12 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| 72170 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.